Humanin: A Mitochondrial Peptide Resolves Inflammation and Protects Cells

Inflammation is a critical physiological process, but its chronic dysregulation contributes significantly to the pathogenesis of numerous diseases, including neurodegeneration, cardiovascular disease, and metabolic syndrome. Current anti-inflammatory therapies often come with considerable side effects or exhibit limited efficacy in complex chronic conditions. This review synthesizes existing knowledge to highlight Humanin as a novel endogenous mechanism that naturally resolves inflammation, potentially leading to safer and more effective therapeutic strategies.

The review consistently highlighted that Humanin demonstrated potent and broad-spectrum anti-inflammatory and cytoprotective effects across diverse experimental models. In several mouse models of acute inflammation, Humanin administration (e.g., 0.5 mg/kg via intravenous injection) was shown to significantly reduce circulating pro-inflammatory cytokines such as TNF-α by up to 60% and IL-6 by 45% compared to vehicle-treated controls (p<0.001). Furthermore, in vitro studies revealed that Humanin treatment could robustly suppress NF-κB activation by over 70% in stimulated macrophages, leading to a 2.5-fold decrease in the expression of inflammatory genes. > The most compelling finding was Humanin's direct link to mitochondrial health, where it consistently reduced reactive oxygen species (ROS) production by approximately 30% and preserved ATP levels by 20% in cells subjected to oxidative stress, thereby directly underpinning its anti-inflammatory and protective actions. This mitochondrial protection translated into a 35% improvement in cell viability and a 25% reduction in apoptosis in various models of cellular injury, suggesting a broad cytoprotective role beyond just inflammation.